NASDAQ:DVAX - Dynavax Technologies Stock Price, News, & Analysis

Dynavax Technologies trades on the NASDAQ under the ticker symbol "DVAX."

Dynavax Technologies Co. (NASDAQ:DVAX) issued its quarterly earnings data on Wednesday, May, 8th. The biopharmaceutical company reported ($0.62) earnings per share for the quarter, topping analysts' consensus estimates of ($0.67) by $0.05. The biopharmaceutical company earned $5.77 million during the quarter, compared to analysts' expectations of $5.95 million. Dynavax Technologies had a negative return on equity of 190.84% and a negative net margin of 1,156.11%. The firm's quarterly revenue was up 3294.1% on a year-over-year basis. During the same period in the prior year, the business posted ($0.63) EPS. View Dynavax Technologies' Earnings History.

Dynavax Technologies is scheduled to release their next quarterly earnings announcement on Monday, August 5th 2019. View Earnings Estimates for Dynavax Technologies.

4 Wall Street analysts have issued 12-month target prices for Dynavax Technologies' stock. Their forecasts range from $13.00 to $30.00. On average, they expect Dynavax Technologies' share price to reach $23.6667 in the next twelve months. This suggests a possible upside of 352.1% from the stock's current price. View Analyst Price Targets for Dynavax Technologies.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Dynavax Technologies in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Dynavax Technologies.

Press coverage about DVAX stock has trended negative on Friday, according to InfoTrie. The research firm identifies positive and negative press coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Dynavax Technologies earned a coverage optimism score of -2.9 on InfoTrie's scale. They also assigned media coverage about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the company's share price in the immediate future.

Some companies that are related to Dynavax Technologies include Zogenix (ZGNX), Zai Lab (ZLAB), Nabriva Therapeutics (NBRV), Prestige Consumer Healthcare (PBH), Madrigal Pharmaceuticals (MDGL), Innoviva (INVA), Endo International (ENDP), Heron Therapeutics (HRTX), Cambrex (CBM), Esperion Therapeutics (ESPR), Gossamer Bio (GOSS), Opko Health (OPK), Aimmune Therapeutics (AIMT), Apellis Pharmaceuticals (APLS) and Phibro Animal Health (PAHC).

Based on aggregate information from My MarketBeat watchlists, some companies that other Dynavax Technologies investors own include Puma Biotechnology (PBYI), Medivation (MDVN), BioMarin Pharmaceutical (BMRN), Incyte (INCY), First Solar (FSLR), Array Biopharma (ARRY), Kite Pharma (KITE), United Continental (UAL), Cara Therapeutics (CARA) and Micron Technology (MU).

Dynavax Technologies' stock is owned by a number of of retail and institutional investors. Top institutional investors include BlackRock Inc. (6.51%), Federated Investors Inc. PA (5.86%), Chicago Capital LLC (3.98%), Eagle Asset Management Inc. (3.74%), Bain Capital Public Equity Management LLC (1.94%) and FMR LLC (1.67%). Company insiders that own Dynavax Technologies stock include David F Novack, David Louis Johnson, Francis Cano, Michael S Ostrach and Robert Coffman. View Institutional Ownership Trends for Dynavax Technologies.

DVAX stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Morgan Stanley, DekaBank Deutsche Girozentrale, Northern Trust Corp, Gables Capital Management Inc., Patriot Financial Group Insurance Agency LLC, Jane Street Group LLC and California State Teachers Retirement System. Company insiders that have sold Dynavax Technologies company stock in the last year include David Louis Johnson, Francis Cano, Michael S Ostrach and Robert Coffman. View Insider Buying and Selling for Dynavax Technologies.

DVAX stock was acquired by a variety of institutional investors in the last quarter, including Chicago Capital LLC, Bain Capital Public Equity Management LLC, Rhenman & Partners Asset Management AB, Macquarie Group Ltd., Marshall Wace North America L.P., Federated Investors Inc. PA, BlackRock Inc. and Assenagon Asset Management S.A.. View Insider Buying and Selling for Dynavax Technologies.

Shares of DVAX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of DVAX stock can currently be purchased for approximately $5.2350.

Dynavax Technologies has a market capitalization of $340.61 million and generates $8.20 million in revenue each year. The biopharmaceutical company earns $-158,900,000.00 in net income (profit) each year or ($2.55) on an earnings per share basis. Dynavax Technologies employs 249 workers across the globe.

The official website for Dynavax Technologies is http://www.dynavax.com/.

Dynavax Technologies' mailing address is 2929 SEVENTH STREET SUITE 100, BERKELEY CA, 94710. The biopharmaceutical company can be reached via phone at 510-848-5100 or via email at [email protected]